CRISPR Therapeutics’ (CRSP) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a report released on Tuesday,Benzinga reports. The firm currently has a $82.00 target price on the stock.

CRSP has been the topic of a number of other research reports. HC Wainwright restated a “buy” rating on shares of CRISPR Therapeutics in a report on Friday, October 9th. Wall Street Zen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Citigroup reiterated a “market outperform” rating on shares of CRISPR Therapeutics in a report on Tuesday. William Blair raised shares of CRISPR Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $55.00 target price on shares of CRISPR Therapeutics in a report on Thursday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $69.69.

CRISPR Therapeutics Trading Down 6.2%

Shares of CRSP opened at $48.56 on Tuesday. The company has a quick ratio of 17.85, a current ratio of 16.21 and a debt-to-equity ratio of 0.36. The firm’s 50 day moving average price is $53.46 and its 200 day moving average price is $52.82. CRISPR Therapeutics has a twelve month low of $44.12 and a twelve month high of $63.45.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, November 2nd. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($1.06) by ($0.09). CRISPR Therapeutics had a negative return on equity of 25.59% and a negative net margin of 1,812.07%. The business had revenue of $12.67 million during the quarter, compared to the consensus estimate of $14.75 million. CRISPR Therapeutics’s revenue for the quarter was up 1311.1% compared to the same quarter last year. As a group, equities research analysts forecast that CRISPR Therapeutics will post -4.46 EPS for the current year.

Insider Buying and Selling

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,040 shares of the company’s stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $49.26, for a total transaction of $51,230.40. Following the completion of the sale, the general counsel owned 95,857 shares of the company’s stock, valued at $4,721,915.82. This represents a 1.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Samarth Kulkarni sold 47,837 shares of the stock in a transaction that occurred on Monday, October 19th. The shares were sold at an average price of $49.78, for a total value of $2,381,325.86. Following the transaction, the chief executive officer owned 311,899 shares in the company, valued at approximately $15,526,332.22. This trade represents a 13.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 93,558 shares of company stock valued at $4,881,663 in the last quarter. Company insiders own 5.20% of the company’s stock.

Institutional Trading of CRISPR Therapeutics

Several large investors have recently modified their holdings of CRSP. Canal Insurance CO bought a new position in CRISPR Therapeutics in the 1st quarter worth $1,670,000. Quantinno Capital Management LP lifted its position in CRISPR Therapeutics by 613.5% during the 1st quarter. Quantinno Capital Management LP now owns 47,989 shares of the company’s stock worth $2,283,000 after acquiring an additional 41,263 shares during the last quarter. KBC Group NV lifted its position in CRISPR Therapeutics by 3,999.9% during the 1st quarter. KBC Group NV now owns 116,847 shares of the company’s stock worth $5,558,000 after acquiring an additional 113,997 shares during the last quarter. Raiffeisen Bank International AG bought a new stake in CRISPR Therapeutics during the second quarter valued at about $1,127,000. Finally, Shah Wealth Advisors LLC bought a new stake in CRISPR Therapeutics during the second quarter valued at about $3,767,000. 69.20% of the stock is owned by institutional investors.

More CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Citigroup raised its price target to $90 from $88 and maintained a Buy rating. Needham also reaffirmed its Buy rating, reflecting continued analyst confidence. Citigroup price-target report Needham rating report
• Positive Sentiment: HC Wainwright and Brookline Capital Markets raised several estimates for future earnings, implying somewhat smaller projected losses in 2026–2027. HC Wainwright maintained its Buy rating. Analyst estimates
• Neutral Sentiment: The company will present clinical data from its investigational gene-edited CAR-T therapy zugo-cel in relapsed or refractory large B-cell lymphoma at the ASH meeting in December. The announcement creates a potential catalyst, but the results have not yet been reported. Zugo-cel clinical data announcement
• Negative Sentiment: CRISPR Therapeutics’ latest quarter missed analyst expectations for both earnings and revenue: EPS was a loss of $1.15 versus a $1.06 loss expected, and revenue was $12.67 million versus $14.75 million expected. CASGEVY revenue reached $99 million, but the double miss may be dampening investor sentiment. CRISPR Therapeutics Q3 2026 earnings analysis
• Negative Sentiment: RBC Capital assigned CRISPR Therapeutics a Hold rating, a more cautious counterpoint to the Buy ratings and raised target from other analysts. RBC Capital rating

About CRISPR Therapeutics

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.